Literature DB >> 2110526

Cell cycle-dependent DHFR and t-PA production in cotransfected, MTX-amplified CHO cells revealed by dual-laser flow cytometry.

M Kubbies1, H Stockinger.   

Abstract

The cell cycle-dependent regulation of the cellular dihydrofolate reductase content (DHFR) and tissue plasminogen activator (t-PA) production and secretion in plasmid-amplified cells was investigated in the DHFR-negative CHO cells transfected with the plasmid pSV-tPA.dhfr. This plasmid, carrying the dhfr and t-PA gene under control of different promotors, was amplified by serial passages in 5 microM methotrexate (MTX) for dhfr gene amplification. The intracellular amount of DHFR was quantitated in viable cells by MTX-FITC labeling and flow cytometric analysis of the FITC fluorescence. In comparison with the original CHO cells, the pSVtPA.dhfr-amplified cells showed a greater than 230-fold increase in MTX-FITC fluorescence. Using dual laser flow cytometry (uv: vital cell cycle with Hoechst 33342; 488 nm: DHFR with MTX-FITC), we show a maximum increase in the intracellular DHFR content during G1 and/or at G1/S transition (100 to 157%), followed by a continuous increase to 200% during S and G2/M. To determine t-PA production CHO cells were sorted from G1-, early/late S-, and G2/M-phase. After 1-, 2-, and 4-h incubation periods, t-PA production was quantitated using a sensitive t-PA ELISA technique. We found that t-PA production and secretion (2-h assay), unlike the expression of DHFR, increased continuously from relatively 100% in G1 to 127% in early S and reached its maximum of 159% in late S, whereas in G2/M-phase it decreased to 118%. Our results show that in pSVtPA.dhfr-coamplified CHO cells gene products DHFR and t-PA both exhibit different cell cycle-correlated accumulation and secretion, respectively, indicating that the brightest MTX-FITC-positive cells (G2/M) do not display the highest t-PA secretion rate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110526     DOI: 10.1016/0014-4827(90)90169-b

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Foreign protein expression from S phase specific promoters in continuous cultures of recombinant CHO cells.

Authors:  G G Banik; P W Todd; D S Kompala
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Relationship between cell size, cell cycle and specific recombinant protein productivity.

Authors:  D R Lloyd; P Holmes; L P Jackson; A N Emery; M Al-Rubeai
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

3.  On-line heat flux measurements improve the culture medium for the growth and productivity of genetically engineered CHO cells.

Authors:  Y H Guan; R B Kemp
Journal:  Cytotechnology       Date:  1999-07       Impact factor: 2.058

4.  The role of the cell cycle in determining gene expression and productivity in CHO cells.

Authors:  D R Lloyd; V Leelavatcharamas; A N Emery; M Al-Rubeai
Journal:  Cytotechnology       Date:  1999-07       Impact factor: 2.058

5.  Engineering Chinese hamster ovary (CHO) cells to achieve an inverse growth - associated production of a foreign protein, beta-galactosidase.

Authors:  F W Lee; C B Elias; P Todd; D S Kompala
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

6.  Cell cycle phase dependent productivity of a recombinant Chinese hamster ovary cell line.

Authors:  Roshni L Dutton; Jeno Scharer; Murray Moo-Young
Journal:  Cytotechnology       Date:  2007-01-25       Impact factor: 2.058

7.  Down-regulation of dihydrofolate reductase inhibits the growth of endothelial EA.hy926 cell through induction of G1 cell cycle arrest via up-regulating p53 and p21(waf1/cip1) expression.

Authors:  Zhewei Fei; Yong Gao; Mingke Qiu; Xianqin Qi; Yuxin Dai; Shuqing Wang; Zhiwei Quan; Yingbin Liu; Jingmin Ou
Journal:  J Clin Biochem Nutr       Date:  2016-02-04       Impact factor: 3.114

Review 8.  Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.

Authors:  Agnieszka Wróbel; Karolina Arciszewska; Dawid Maliszewski; Danuta Drozdowska
Journal:  J Antibiot (Tokyo)       Date:  2019-10-02       Impact factor: 2.649

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.